Tranexamic Acid Treatment of Life-Threatening Hematuria in Polycystic Kidney Disease
A 41-year-old woman with autosomal dominant polycystic kidney disease had chronic kidney disease class IV. She presented 10 days postpartum with a 4-day history of severe hematuria, left flank pain, and anemia, hemoglobin 62 g/L. CT scan showed massively
Turki AlAmeel, Michael West
doaj +1 more source
Development of Two New Colorimetric Methods for Determination of Tranexamic Acid [PDF]
Tranexamic acid is a non UV/visible absorbing compound. Thus, a suitable chromogen is needed to react with it forming absorbing chromophore that can be used for simple and sensitive determination of tranexamic ...
Abdalla, Maha
core
Topical tranexamic acid (TXA) for the management of a bleeding arteriovenous fistula
Tranexamic acid (TXA) is increasing in use in the Emergency Department (ED). While its topical uses have largely been observed in the management of epistaxis, other applications are utilized.
Eberle, Maria Loren +2 more
core +1 more source
Living With Factor VII Deficiency—A Mixed Methods Study
ABSTRACT Background Factor VII deficiency (FVIID) is a rare autosomal recessive disorder, resulting in potentially unpredictable and life‐threatening bleeding. The prevalence of symptomatic patients is 1 in 300,000. Treatment is mostly given following bleeding, but those with the lowest levels may be offered prophylaxis.
Simon Fletcher +3 more
wiley +1 more source
Perioperative Management in Persons With Haemophilia on Rebalancing Therapies: A Narrative Review
ABSTRACT Introduction Perioperative management in haemophilia often requires on‐demand use of clotting factor concentrates (CFC) and/or bypassing agents. Rebalancing agents (fitusiran, concizumab, marstacimab) offer a novel approach to prophylaxis by modulating endogenous anticoagulant pathways to restore haemostatic balance.
Amanda M. Henderson +2 more
wiley +1 more source
NASPAG Clinical Consensus: Use of Tranexamic Acid in the Treatment of Heavy Menstrual Bleeding
Heavy menstrual bleeding is a common condition encountered in the adolescent patient population. The objective of this consensus guideline is to provide the latest evidence regarding the use of tranexamic acid as a treatment modality for heavy menstrual ...
French, Amanda +4 more
core +1 more source
Shared Decision‐Making in Haemophilia Involves More Treatment Differentiators in 2026
ABSTRACT Introduction Shared decision‐making regarding treatment choice in haemophilia care has become increasingly more complex and essential due to the availability of several innovative therapeutics that are characterized by their own advantages and limitations, which need to be tailored to individual patient needs.
Quentin Van Thillo +2 more
wiley +1 more source
Treatment of Melasma with Tranexamic Acid Essence Combined with Iontophoresis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial [PDF]
Linghong Guo,1,2 Xu Liu,1,2 Qingfeng Liu,1,2 Xiaoqin Xie,1,2 Xian Jiang1,2 1Department of Dermatology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Laboratory of Dermatology, Clinical Institute of Inflammation and ...
Liu X, Guo L, Xie X, Jiang X, Liu Q
core
Effect of Tranexamic Acid after Cardiac Surgery in Children
Background: The antifibrinolytic drug tranexamic acid (TA) decreases blood loss in Pediatric patients under going cardiac Surgery. However its efficacy has not been extensively studied in children.
KA Hasan +8 more
core +1 more source
ABSTRACT Objectives The aim of this work is to assess and compare the impact of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKA) during and immediately after periodontal nonsurgical therapy. Materials and Methods A prospective observational cohort study was conducted with patients who presented a history of cardiovascular disease ...
F. Berton +5 more
wiley +1 more source

